{"disease":{"id":"immunocompromised","name":"immunocompromised"},"drugs":{"marketed":[{"drug_id":"acyclovir-sodium","indication_name":"Herpes Simplex in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ACYCLOVIR SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"acyclovir-sodium","indication_name":"Varicella-Zoster in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ACYCLOVIR SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis B (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Zoster (shingles) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (seasonal) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (H1N1) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Varicella (chickenpox) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Pneumococcal disease (PCV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Zoster (shingles) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (seasonal) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (H1N1) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Varicella (chickenpox) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Pneumococcal disease (PCV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"cidofovir","indication_name":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vistide","generic_name":"CIDOFOVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"cidofovir","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"CMV Retinitis in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"foscarnet","indication_name":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"vistide","indication_name":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vistide","company_name":"Gustave Roussy, Cancer Campus, Grand Paris","drug_phase":"marketed","molecular_target":"DNA polymerase catalytic subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"prevnar-20","indication_name":"Immunocompromised adults (CLL, HIV, autoimmune)","indication_type":"pipeline","phase":"phase_3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar 20","generic_name":"pneumococcal 20-valent conjugate vaccine (PCV20)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae capsular polysaccharides (20 serotypes)","drug_class":"Pneumococcal conjugate vaccine","quality_score":80,"revenue":"6400","mechanism":"20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes"}],"offLabel":[],"totalMarketed":33,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT00904579","title":"Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease","phase":"","overall_status":"COMPLETED","enrollment_count":19929901,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05020145","title":"COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1277747,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05439044","title":"A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Prophylaxis and Curative of Covid-19 (COVIMAB)","phase":"","overall_status":"COMPLETED","enrollment_count":4235,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04043793","title":"ICU-acquired Colonization and Infection Related to MDR in Immunocompromised Patients","phase":"","overall_status":"COMPLETED","enrollment_count":759,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT06599658","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":660,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT04805125","title":"Immunocompromised Swiss Cohorts Based Trial Platform","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":610,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT04680884","title":"Empirical Steroids and/or Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":420,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05605145","title":"PCP in Immunocompromised Population in Southern China","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"First Affiliated Hospital of Guangxi Medical University","has_results":false},{"nct_id":"NCT06683937","title":"Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03808922","title":"Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":274,"lead_sponsor_name":"Ansun Biopharma, Inc.","has_results":false},{"nct_id":"NCT04047719","title":"Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens","phase":"","overall_status":"COMPLETED","enrollment_count":257,"lead_sponsor_name":"Karius, Inc.","has_results":false},{"nct_id":"NCT06387667","title":"Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"New Valley University","has_results":false},{"nct_id":"NCT06890078","title":"Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT01837277","title":"Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Fundação Bahiana de Infectologia","has_results":true},{"nct_id":"NCT07120464","title":"Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations","phase":"","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Liaoning Chengda Biotechnology CO., LTD","has_results":false},{"nct_id":"NCT05216588","title":"Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.","phase":"","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"ANRS, Emerging Infectious Diseases","has_results":false},{"nct_id":"NCT06738082","title":"Influenza Vaccine Elicited Immune Response in Immunocompromised Patients","phase":"","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT05726006","title":"Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults.","phase":"","overall_status":"UNKNOWN","enrollment_count":133,"lead_sponsor_name":"Universiti Putra Malaysia","has_results":false},{"nct_id":"NCT03168815","title":"Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":98,"lead_sponsor_name":"Mount Sinai Hospital, Canada","has_results":false},{"nct_id":"NCT03597269","title":"Evaluation of Pneumococcal Vaccine Coverage","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Fondation Hôpital Saint-Joseph","has_results":false},{"nct_id":"NCT05074433","title":"A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05597761","title":"Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"Oliver Cornely, MD","has_results":false},{"nct_id":"NCT06610643","title":"Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03262584","title":"Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Karius, Inc.","has_results":false},{"nct_id":"NCT07295535","title":"Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT03425526","title":"Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05545319","title":"A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT00923832","title":"Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis","phase":"","overall_status":"COMPLETED","enrollment_count":null,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":28},"guidelines":[],"source":"Drug Landscape verified database"}